Melanoma

Nivolumab Monotherapy Provides Long Term Benefit Advanced Melanoma

Nivolumab Monotherapy Provides Long Term Benefit Advanced Melanoma

By

Dacarbazine, although once a staple of melanoma therapy, essentially has no current role in the treatment of any type or stage of melanoma.

BRAF Splice Variants May Mediate Resistance to RAF Inhibitors in Patients with Melanoma

BRAF Splice Variants May Mediate Resistance to RAF Inhibitors in Patients with Melanoma

By

The discovery could provide opportunities to target resistance driven by aberrantly spliced forms of BRAF V600E.

Encorafenib Plus Binimetinib Offers a New Option for MEK+BRAF Inhibition

Encorafenib Plus Binimetinib Offers a New Option for MEK+BRAF Inhibition

By

In the immunotherapy era, the optimal setting and sequencing of BRAF+MEK inhibition remains unresolved.

Pembrolizumab With Dabrafenib and Trametinib Shows Efficacy, But High TRAEs, in Melanoma

Pembrolizumab With Dabrafenib and Trametinib Shows Efficacy, But High TRAEs, in Melanoma

By

Pembrolizumab plus dabrafenib and trametinib showed a nonsignificant improvement in PFS, but also higher rates of grade 3 to grade 5 TRAEs in advanced melanoma.

First-Line Nivolumab Alone or With Ipilimumab Continues to Show Durable Survival Benefits in Advanced Melanoma

First-Line Nivolumab Alone or With Ipilimumab Continues to Show Durable Survival Benefits in Advanced Melanoma

By

First-line nivolumab with or without ipilimumab continues to show durable survival benefits in advanced, unresectable melanoma.

Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma

Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma

By

T-VEC elicited substantially higher ORR in a real-world population compared with the rate that was seen in the drug maker's phase 3 trial.

Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC

Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC

By

Researchers investigated whether the rates of immune-related adverse events linked to treatment with nivolumab or pembrolizumab were similar across 2 different cancer types.

The Optimal Neoadjuvant Regimen of Checkpoint Inhibitors in High-Risk Melanoma Is Unclear

The Optimal Neoadjuvant Regimen of Checkpoint Inhibitors in High-Risk Melanoma Is Unclear

By

Treatment with ipilimumab plus nivolumab in the neoadjuvant setting resulted in high patient response rates — but it was linked to high toxicity, as well.

Neoadjuvant Combination Checkpoint Inhibition May Be Feasible for Stage III Melanoma

Neoadjuvant Combination Checkpoint Inhibition May Be Feasible for Stage III Melanoma

By

Future studies on checkpoint inhibition in melanoma must evaluate ways of reducing toxicity.

Combination Immunotherapy Shown To Be Clinically Meaningful in Melanoma Metastatic to the Brain

Combination Immunotherapy Shown To Be Clinically Meaningful in Melanoma Metastatic to the Brain

By

Updated results show prolonged responses to brain metastases.

Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response

Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response

By

Existing studies that summarize the risks of breast implants are not adequately powered to detect all harms, alleged authors of a study including nearly 100,000 patient outcomes.

Predicting Response to Immunotherapy in Late-Stage Melanoma

Predicting Response to Immunotherapy in Late-Stage Melanoma

By

A new model has the potential to identify patients with melanoma who could benefit from treatment with checkpoint inhibitors.

Exploring the Role of Immunotherapy in Melanoma Brain Metastases

Exploring the Role of Immunotherapy in Melanoma Brain Metastases

By

Although checkpoint inhibitors are active against melanoma-linked brain metastases, researchers are interested in exploring combination approaches.

Predictors of Response to Checkpoint Inhibitors in Melanoma Revealed

Predictors of Response to Checkpoint Inhibitors in Melanoma Revealed

By

A computational tool appears to accurately tease out the portion of patients who might respond to checkpoint inhibitors from those who are likely to be resistant.

Limited Local Lymph Node Excision Plus Radiotherapy May Be Effective in Melanoma

Limited Local Lymph Node Excision Plus Radiotherapy May Be Effective in Melanoma

By

Previous studies have evaluated the effects of limited local node excision plus radiotherapy among patients with melanoma in this subgroup, but had conflicting results.

Adjuvant Bevacizumab May Not Improve Overall Survival in Resected Melanoma

Adjuvant Bevacizumab May Not Improve Overall Survival in Resected Melanoma

By

Previous studies have demonstrated that the vascular endothelial growth factor inhibitor bevacizumab is active in melanoma, and may be effective in the maintenance setting.

Tapping Social Media for Skin Cancer Prevention: What You Can Do

Tapping Social Media for Skin Cancer Prevention: What You Can Do

Any images and personal stories that remind people about skin cancer, what to look for, even scars after surgery, really help save lives.

Frequency of Tanning, Risk for Melanoma Higher in Gym Tanners

Frequency of Tanning, Risk for Melanoma Higher in Gym Tanners

By

The use of tanning beds and/or booths and their availability in gyms may increase the frequency of indoor tanning for physically active adults, a combination that further exacerbates their risk for melanoma.

Do Sunless Tanners Have Fewer Skin Cancer Risk Behaviors?

Do Sunless Tanners Have Fewer Skin Cancer Risk Behaviors?

By

People who elect to undergo sunless tanning tend to continue behaviors that could increase their risk of skin cancer.

Skin Cancer Education May Improve Sun Protection Practices Among Organ Transplant Recipients

Skin Cancer Education May Improve Sun Protection Practices Among Organ Transplant Recipients

The use of multiple sun protection measures was defined as the use of 2 or more of these measures more than 50% of the time when the individual was outdoors.

Next-Generation Sequencing Adds Value by Detecting More Mutations Than Polymerase Chain Reaction in Melanoma

Next-Generation Sequencing Adds Value by Detecting More Mutations Than Polymerase Chain Reaction in Melanoma

By

Since next-generation sequencing reflex testing has been implemented at Case Western Reserve University School of Medicine, several cases of potentially actionable mutations have been identified that would not have been caught by PCR alone.

Reprogramming T Cells Without Using Viral Vectors

Reprogramming T Cells Without Using Viral Vectors

By

According to recent research, scientists may not need to rely on the use of viral vectors to edit the genes of primary immune cells when creating cell and gene therapies.

FDA Approves Encorafenib Plus Binimetinib for <i>BRAF V600E, V600K</i> Mutation-Positive Melanoma

FDA Approves Encorafenib Plus Binimetinib for BRAF V600E, V600K Mutation-Positive Melanoma

By

The FDA based their approval on findings from the phase 3 COLUMBUS study, in which researchers randomly assigned patients with BRAF V600-mutant melanoma to receive encorafenib plus binimetinib, encorafenib, or vemurafenib.

Novel Targets, Treatments Needed for Melanomas Not Responding to Targeted Immunotherapies

Novel Targets, Treatments Needed for Melanomas Not Responding to Targeted Immunotherapies

By

Novel targets in the treatment of melanoma was a hot topic of discussion during the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.

Radiation and Immunotherapy Show Possible Survival Advantage in Melanoma-Related Brain Metastases

Radiation and Immunotherapy Show Possible Survival Advantage in Melanoma-Related Brain Metastases

By

Results from a small study show that PD-1 inhibitors could work synergistically with radiosurgery to promote slightly longer survival times.

FDA Accepts sBLA for Pembrolizumab as Adjuvant Therapy for Melanoma

FDA Accepts sBLA for Pembrolizumab as Adjuvant Therapy for Melanoma

By

If approved, the new indication could mean pembrolizumab could be used for patients with melanoma.

In Melanoma, Older Adults Could Benefit More From Treatment With PD-1 Inhibitors

In Melanoma, Older Adults Could Benefit More From Treatment With PD-1 Inhibitors

By

Patient age should play a role in drug development strategies for melanoma, researchers of a new study say.

Long-Term Data Show Nivolumab May Provide Sustained Benefit Compared With Ipilimumab

Long-Term Data Show Nivolumab May Provide Sustained Benefit Compared With Ipilimumab

By

Preliminary findings from CheckMate 238 show treatment with nivolumab significantly prolonged recurrence-free survival compared with ipilimumab in patients with resected stage III/IV melanoma after a minimum 18-month follow-up.

Complete Lymph Node Dissection May Not Improve Outcomes in Melanoma

Complete Lymph Node Dissection May Not Improve Outcomes in Melanoma

By

When compared with watchful waiting, CLND did not improve survival outcomes among patients with malignant melanoma who have positive SLNB.

Latest AJCC Edition Staging System May Not Be As Effective in Differentiating Survival in Melanoma

Latest AJCC Edition Staging System May Not Be As Effective in Differentiating Survival in Melanoma

By

Study authors conducted a study comparing the prognostic and discriminatory ability for survival with the 7th and 8th Editions.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs